PAVmed Inc. - FORM 8-K - April 11, 2017

Attached files

file	filename
EX-99.1 - EXHIBIT 99.1 - PAVmed Inc.	t1701129_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 10, 2017

PAVMED INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-37685

47-1214177

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

One Grand Central Place, Suite 4600, New York, New York		10165
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 949-4319

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events.

On April 10, 2017, PAVmed Inc., a Delaware corporation (the “Corporation”), announced it filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2017 relating to the Corporation’s previously announced intention to effectuate a registered exchange offer whereby each share of the Corporation’s common stock, par value $0.001 per share (the “Common Stock”) will become exchangeable for a unit consisting of one share of Common Stock and one newly-issued warrant (the “Exchange”). The intention to effectuate the Exchange was disclosed in the Current Report on Form 8-K which the Corporation filed with the SEC on February 23, 2017. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

Description

99.1

Press release of PAVmed Inc. dated April 10, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 11, 2017	PAVMED INC.

	By:	/s/ Lishan Aklog
		Lishan Aklog, M.D.
		Chief Executive Officer

Exhibit Index